The Worldwide Innovative Networking Consortium in personalized cancer medicine plans to use Foundation Medicine's cancer genome profiling test in an upcoming clinical trial, the company said last week.
A company spokesperson told Clinical Sequencing News that the trial will involve 200 patients, who will be enrolled starting in early 2013. Each patient will be evaluated with the firm's sequencing-based test, FoundationOne, and be matched to a targeted therapy where possible.